+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ASEAN and China Biosimilars Market by Molecule Type, and Application: Opportunity Analysis and Industry Forecast, 2017 - 2025

  • ID: 4744595
  • Report
  • Region: ASEAN, China
  • 130 pages
  • Allied Analytics LLP
1 of 4
ASEAN and China Biosimilars Market Overview:

The ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that are anticipated to expire in future. The development and validation of biosimilars with reference biologics is a crucial part of the overall process. The key driving factor for biosimilars is their implied ability of providing more cost-effective treatment than branded biologics.

Key players operating in the pharmaceuticals industry are largely investing in the development of biosimilars that can be applied for the treatment of several chronic medical conditions. Biosimilars have the potential to offer up to 30% cost reduction as compared to branded biologics. This is attributed to the compact validation pathways that reduce the additional cost of clinical trials, which further assist manufacturers to achieve scale economies. The key contributing factor to the growth in demand for biosimilars across the ASEAN and Chinese market is the patent expiration of most of the blockbuster drugs in the past few years. However, the biosimilars industry is witnessing issues pertaining to achieving product efficiency while maintaining the required production capacity. This plays a pivotal role in the biosimilars industry considering the large population of ASEAN countries along with China. Progress in improving the product efficiency and quantity is expected to open new avenues for the expansion of the biosimilars market across ASEAN and China.

The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.

Key Benefits ASEAN and China Biosimilars Market:

The study provides an in-depth analysis of the ASEAN and China biosimilars market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
A qualitative analysis of the driving factors and opportunities help analyze the competitive scenario of the market.
Porter’s five forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.

ASEAN and China Biosimilars Key Market Segments:

By Molecule Type

Human Growth Hormone
Erythropoietin
Monoclonal Antibody
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Peptide

By Application

Blood Disorders
Oncology Diseases
Chronic and Autoimmune Diseases
Rheumatoid Arthritis (RA)
Diabetes
Glaucoma
Others
Growth Hormone Deficiency
Others

By Region

China
ASEAN Region
Singapore
Malaysia
Thailand
Indonesia
Philippines
Vietnam
Rest of ASEAN Countries

Key Market Players

3SBIO Inc.
Qilu Pharmaceutical
Novartis International AG (Sandoz International GmbH)
Pfizer Inc. (Hospira)
STADA Arzneimittel
Beijing SL Pharmaceutical Co., Ltd.
Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)
Amgen Inc.
AstraZeneca Plc
Teva Pharmaceutical Industries Ltd.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter 2: EXECUTIVE SUMMARY
2.1. CXO perspective

Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Asean biosimilars market size and forecast
3.5. China biosimilars market size and forecast
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Various blockbusters going off patent
3.6.1.2. High prevalence of chronic diseases among ageing population
3.6.1.3. Lower cost of biosimilars drugs than original biologics
3.6.2. Restraints
3.6.2.1. High initial investment in research and development
3.6.2.2. Medical efficacy and patient safety
3.6.3. Opportunity
3.6.3.1. Emergence of bio-better drugs

Chapter 4: ASEAN AND CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Human growth hormone
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.3. Erythropoietin
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.4. Monoclonal antibodies
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast
4.5. Insulin
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast
4.6. Interferon
4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast
4.7. Granulocyte-Colony Stimulating Factor
4.7.1. Key market trends and growth opportunities
4.7.2. Market size and forecast
4.8. Peptide
4.8.1. Key market trends and growth opportunities
4.8.2. Market size and forecast

Chapter 5: ASEAN AND CHINA BIOSIMILARS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Blood Disorders
5.2.1. Market size and forecast
5.3. Oncology Diseases
5.3.1. Market size and forecast
5.4. Chronic and Autoimmune Diseases
5.4.1. Market size and forecast
5.4.2. Rheumatoid Arthritis (RA)
5.4.2.1. Market size and forecast
5.4.3. Diabetes
5.4.3.1. Market size and forecast
5.4.4. Glaucoma
5.4.4.1. Market size and forecast
5.4.5. Others
5.4.5.1. Market size and forecast
5.5. Growth hormone deficiency
5.5.1. Market size and forecast
5.6. Others
5.6.1. Market size and forecast

Chapter 6: COMPANY PROFILES
6.1. 3SBIO INC.
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments
6.2. Qilu Pharmaceutical
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Key strategic moves and developments
6.3. Novartis International AG (Sandoz International GmBH)
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.3.6. Key strategic moves and developments
6.4. Pfizer Inc. (Hospira)
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments
6.5. STADA Arzneimittel
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Product portfolio
6.5.5. Business performance
6.6. Beijing SL Pharmaceutical Co., Ltd.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.7. Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments
6.8. Amgen Inc.
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance
6.8.6. Key strategic moves and developments
6.9. AstraZeneca Plc
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product Portfolio
6.9.5. Business performance
6.10. Teva Pharmaceutical Industries Ltd.
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance

List Of Tables
Table 01. Asean Biosimilars Market, By Country, 2017-2025 ($Million)
Table 02. Off Going Patents 2013-2016
Table 03. Asean Biosimilars Market, By Molecule Type, 2017-2025 ($Million)
Table 04. China Biosimilars Market, By Molecule Type, 2017-2025 ($Million)
Table 05. Asean And China Biosimilars Market, By Molecule Type, 2017-2025 ($Million)
Table 06. Biosimilars Market For Human Growth Hormone, By Region, 2017-2025 ($Million)
Table 07. Biosimilars Market For Erythropoietin, By Region, 2017-2025 ($Million)
Table 08. Monoclonal Antibodies From Companeis In China
Table 09. Biosimilars Market For Monoclonal Antibodies, By Region, 2017-2025 ($Million)
Table 10. Prevalence Of Diabetes In China And Asean Countries
Table 11. Biosimilars Market For Insulin, By Region, 2017-2025 ($Million)
Table 12. Biosimilars Market For Interferon, By Region, 2017-2025 ($Million)
Table 13. Biosimilars Market For Granulocyte-Colony Stimulating Factor, By Region, 2017-2025 ($Million)
Table 14. Biosimilars Market For Peptide, By Region, 2017-2025 ($Million)
Table 15. Asean Biosimilars Market, By Application, 2017-2025 ($Million)
Table 16. China Biosimilars Market, By Application, 2017-2025 ($Million)
Table 17. Asean And China Biosimilars Market, By Application, 2017-2025 ($Million)
Table 18. Biosimilars Market For Blood Disorders, By Region, 2017-2025 ($Million)
Table 19. Biosimilars Market For Oncology Diseases, By Region, 2017-2025 ($Million)
Table 20. Biosimilars Market For Chronic And Autoimmune Diseases, By Region, 2017-2025 ($Million)
Table 21. Biosimilars Market For Rheumatoid Arthritis (Ra), By Region, 2017-2025 ($Million)
Table 22. Biosimilars Market For Diabetes, By Region, 2017-2025 ($Million)
Table 23. Biosimilars Market For Glaucoma, By Region, 2017-2025 ($Million)
Table 24. Biosimilars Market For Others, By Region, 2017-2025 ($Million)
Table 25. Biosimilars Market For Growth Hormone Deficiency, By Region, 2017-2025 ($Million)
Table 26. Biosimilars Market For Others, By Region, 2017-2025 ($Million)
Table 27. 3Sbio: Company Snapshot
Table 28. 3Sbio: Application Portfolio
Table 29. Qilu: Company Snapshot
Table 30. Sandoz: Company Snapshot
Table 31. Novartis: Operating Segments
Table 32. Novartis Ag: Product Portfolio
Table 33. Pfizer: Company Snapshot
Table 34. Pfizer: Operating Segments
Table 35. Pfizer: Product Portfolio
Table 36. Stada: Company Snapshot
Table 37. Stada: Operating Segments
Table 38. Stada: Product Portfolio
Table 39. Beijing Sl: Company Snapshot
Table 40. Beijing Sl: Operating Segments
Table 41. Beijing Sl: Product Portfolio
Table 42. Fosun Pharmaceutical: Company Snapshot
Table 43. Fosun Pharmaceutical: Operating Segments
Table 44. Fosun Pharmaceutical: Pipeline Product Portfolio
Table 45. Amgen: Company Snapshot
Table 46. Amgen: Product Portfolio
Table 47. Astrazeneca: Company Snapshot
Table 48. Astrazeneca: Operating Segments
Table 49. Astrazeneca: Product Portfolio
Table 50. Teva: Company Snapshot
Table 51. Teva: Operating Segments
Table 52. Teva: Pipeline Product Portfolio

List of Figures
Figure 01. Asean And China Market Segmentation
Figure 02. Top Winning Strategies, By Year, 2015-2018*
Figure 03. Top Winning Strategies, By Development, 2015-2018* (%)
Figure 04. Top Winning Strategies, By Company, 2015-2018*
Figure 05. Moderate Bargaining Power Of Suppliers
Figure 06. Moderate Bargaining Power Of Buyers
Figure 07. Low Threat Of Substitution
Figure 08. Moderate Threat Of New Entrant
Figure 09. Moderate Competitive Rivalry
Figure 10. Asean Biosimilars Market, 2017-2025 ($Million)
Figure 11. China Biosimilars Market, 2017-2025 ($Million)
Figure 12. Asean And China Biosimilars Market: Restraints, Drivers, And Opportunity
Figure 13. 3Sbio, 2015-2017 ($Million)
Figure 14. Novartis: Net Sales, 2015-2017 ($Million)
Figure 15. Novartis: Revenue Share By Segment, 2017 (%)
Figure 16. Novartis: Revenue Share By Geography, 2017 (%)
Figure 17. Pfizer: Net Sales, 2015-2017 ($Million)
Figure 18. Pfizer: Revenue Share By Segment, 2017 (%)
Figure 19. Pfizer: Revenue Share By Geography, 2017 (%)
Figure 20. Stada: Net Sales, 2015-2017 ($Million)
Figure 21. Stada: Revenue Share By Segment, 2017 (%)
Figure 22. Stada: Revenue Share By Geography, 2017 (%)
Figure 23. Fosun Pharmaceutical: Net Sales, 2015-2017 ($Million)
Figure 24. Fosun Pharmaceutical: Revenue Share By Segment, 2017 (%)
Figure 25. Fosun Pharmaceutical: Revenue Share By Geography, 2017 (%)
Figure 26. Amgen: Net Sales, 2015-2017 ($Million)
Figure 27. Amgen: Revenue Share By Product, 2017 (%)
Figure 28. Amgen: Revenue Share By Geography, 2017 (%)
Figure 29. Astrazeneca: Revenue, 2015-2017 ($Million)
Figure 30. Astrazeneca: Revenue Share By Geography, 2017 (%)
Figure 31. Teva: Net Sales, 2015-2017 ($Million)
Figure 32. Teva: Revenue Share By Segment, 2017 (%)
Figure 33. Teva: Revenue Share By Geography, 2017 (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled, 'ASEAN and China Biosimilars Market by Molecule Type, and Application: Opportunity Analysis and Industry Forecast, 2018-2025', the ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biosimilars are replicas of biologic drugs that are approved by the concerned regulatory authorities for use in the treatment of several medical indications. According to the U.S. law, a biosimilar is approved based on its similarity to the FDA-approved biological product, also known as the reference product.

Biosimilars have gained immense traction over the years as they are anticipated to offer immense savings to healthcare systems along with increased access to the advanced treatments. The principles behind development of biosimilars are same and regulations for biosimilars play a vital role in maintaining the viability and balance between original and biosimilar products. However, stringency of these regulations is expected to create hurdles in the growth of the biosimilar industry. In addition, rise in prevalence of chronic diseases such as cancer and diabetes, has fueled the demand for pharmaceutical drugs, especially the high-priced patented drugs. In such cases, the cost of reference biologics exceeds the healthcare expenditure. This increased cost of drugs triggered the need for biosimilar products that provide similar efficacy and quality at low cost.

The ASEAN and China biosimilars market is segmented based on molecule type, application, and region. Based on molecule type, monoclonal antibodies segment has dominated the market from 2017 to 2025. Whereas, the human growth hormone molecule segment registered the highest CAGR during 2018-2025 in the ASEAN and China biosimilars market. Upsurge in unmet needs for cancers has propelled global pharmaceutical giants to invest in the development of monoclonal antibody biosimilars and increase their accessibility across the ASEAN countries and China.

Key Findings of the ASEAN and China Biosimilars Market:

Indonesia generated the highest revenue in the ASEAN biosimilars market in 2017 and is expected to remain dominant throughout the forecast period.
Based on molecule type, the erythropoietin segment accounted for the second highest share in the ASEAN and China biosimilars market in 2017 and is expected to maintain this trend throughout the forecast period.
Based on application, the blood disorders segment is estimated to rank second in terms of revenue in both, the ASEAN, and the China biosimilars market throughout the analysis period.
The diabetes segment generated the highest CAGR from 2018 to 2025 in the ASEAN and China biosimilars market.

Based on application, the oncology diseases segment generated the highest revenue in 2017 and is anticipated to maintain this trend throughout the forecast period. In addition, the chronic and autoimmune diseases segment is anticipated to grow at the fastest pace from 2018 to 2025 in the market. The demand for biosimilars in the treatment of oncological indications has witnessed considerable increase in recent years. This is attributed to the escalating cost of cancer care that imposes significant burden on the healthcare systems across the ASEAN countries and China.

The major companies profiled in the report include 3SBIO Inc., Qilu Pharmaceutical, Novartis International AG (Sandoz International GmBH), Pfizer Inc. (Hospira), STADA Arzneimittel, Beijing SL Pharmaceutical Co., Ltd., Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.), Amgen Inc., AstraZeneca Plc, and Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4744595
Adroll
adroll